Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
435.04
-2.73 (-0.62%)
Apr 16, 2025, 4:00 PM EDT - Market closed
Elevance Health Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Elevance Health stock have an average target of 524.4, with a low estimate of 405.4 and a high estimate of 631. The average target predicts an increase of 20.54% from the current stock price of 435.04.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevance Health stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 9 | 9 | 9 | 9 | 9 | 8 |
| Hold | 1 | 1 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 15 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy → Hold Downgrades $625 → $529 | Buy → Hold | Downgrades | $625 → $529 | +21.60% | Apr 15, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $480 → $510 | Strong Buy | Maintains | $480 → $510 | +17.23% | Apr 11, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $518 | Strong Buy | Initiates | $518 | +19.07% | Apr 9, 2025 |
| Mizuho | Mizuho | Buy Maintains $455 → $505 | Buy | Maintains | $455 → $505 | +16.08% | Apr 9, 2025 |
| Argus Research | Argus Research | Hold Reiterates $405 | Hold | Reiterates | $405 | -6.81% | Jan 29, 2025 |
Financial Forecast
Revenue This Year
195.09B
from 176.81B
Increased by 10.34%
Revenue Next Year
209.54B
from 195.09B
Increased by 7.41%
EPS This Year
34.50
from 25.68
Increased by 34.34%
EPS Next Year
39.49
from 34.50
Increased by 14.48%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 213.9B | 231.4B | 252.3B | |
| Avg | 195.1B | 209.5B | 227.9B | |
| Low | 186.2B | 199.3B | 212.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 21.0% | 18.6% | 20.4% | |
| Avg | 10.3% | 7.4% | 8.7% | |
| Low | 5.3% | 2.1% | 1.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.33 | 43.68 | 50.66 | ||
| Avg | 34.50 | 39.49 | 46.02 | ||
| Low | 30.32 | 36.20 | 41.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 41.5% | 26.6% | 28.3% | ||
| Avg | 34.3% | 14.5% | 16.5% | ||
| Low | 18.1% | 4.9% | 6.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.